Cardium Therapeutics (NYSE:CXM) appealed to U.S. federal regulators for 510(k) clearance of its Excellagen wound care product after making several modifications and including more specific labeling.
Wound Therapy
Operating profits rise for KCI despite Q2 sales slide
Operating profits rose 13.1% during the 2nd quarter for Kinetic Concepts Inc., despite a nearly 4% sales decline for the wound management company.
San Antonio, Texas-based KCI reported operating profits of $110.8 million on sales of $317.8 million for the 3 months ended June 30, according to a regulatory filing.
Second-quarter losses soar for Derma Sciences
Second-quarter losses soared for Derma Sciences (NSDQ:DSCI), but the wound care company still managed to beat Wall Street’s earnings expectations by 4¢.
Princeton, N.J.-based Derma Sciences reported losses of $7.3 million, or 43¢ per share, on sales of $18.1 million for the 3 months ended June 30. Losses grew 59.8% despite a 3.1% top-line gain, compared with Q2 2012.
KCI to drop $485M on wound care company Systagenix
Kinetic Concepts Inc. said it agreed to acquire 1 of its private wound-care peers, Systagenix, for $485 million.
San Antonio, Texas-based KCI said the deal brings a large suite of complementary advanced wound care products into its portfolio.
Soluble Systems drums up $3.5M from dozens of investors
Wound care company Soluble Systems wrapped up a $3.5 million private equity funding round, raising most of the cash from existing company insiders, board members and executives.
Of the total 57 investors, only 10 are 1st-timers and the remaining are current stakeholders who chose to up the ante in the most recent round. None of the new cash came from venture capital firms, the company told MassDevice.com.
Alliqua board members and executives drive recent financing round
Wound dressing device maker Alliqua closed a $3 million equity financing round, largely backed by an insider group of board members and executives.
Alliqua drummed up the cash over the course of 3 months through sale of common stock, according to a company statement. Accredited investors paid 81¢ per share for equity, coupled with a warrant to purchase an additional share at 97¢ apiece.
Combat Medical Systems wins 1st-of-its kind approval for tourniquet
Combat Medical Systems won FDA approval for its atypical tourniquet, designed to prevent deaths from uncontrolled bleeding that most often takes place because of roadside and terrorist bombings.
This is the 1st device of its kind approved to treat unmanageable amputations and pelvic injuries, and it has already been shown to save lives based on limited use on soldiers in Afghanistan and traumatic civilian situations domestically, the company said. Uncontrolled bleeding is the number 1 cause of death in combat.
Cone Health joins Premier healthcare alliance
Red Cross, biotech firm sue Johnson & Johnson over bandage sealant patents
Novadaq, KCI spike Luna wound imaging deal | Wall Street Beat
Novadaq Technologies (TSE:NDQ) said it and wound care giant Kinetic Concepts agreed to an amicable end to the co-development deal they inked in 2011 for the Luna wound imaging device.